KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Gains from Investment Securities (2020 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed Gains from Investment Securities for 6 consecutive years, with -$2.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gains from Investment Securities rose 82.96% year-over-year to -$2.9 million, compared with a TTM value of -$19.8 million through Dec 2025, down 21.15%, and an annual FY2025 reading of -$9.5 million, up 41.55% over the prior year.
  • Gains from Investment Securities was -$2.9 million for Q4 2025 at Recursion Pharmaceuticals, up from -$17.0 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $5.9 million in Q2 2024 and bottomed at -$17.0 million in Q4 2024.
  • Average Gains from Investment Securities over 5 years is -$1.5 million, with a median of -$427500.0 recorded in 2022.
  • The sharpest move saw Gains from Investment Securities crashed 1530.72% in 2021, then surged 975.62% in 2023.
  • Year by year, Gains from Investment Securities stood at $2.5 million in 2021, then crashed by 118.3% to -$453000.0 in 2022, then plummeted by 893.6% to -$4.5 million in 2023, then crashed by 277.45% to -$17.0 million in 2024, then surged by 82.96% to -$2.9 million in 2025.
  • Business Quant data shows Gains from Investment Securities for RXRX at -$2.9 million in Q4 2025, -$17.0 million in Q4 2024, and -$5.8 million in Q3 2024.